<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03286023</url>
  </required_header>
  <id_info>
    <org_study_id>CYM6 Brain metastases CFB 1</org_study_id>
    <nct_id>NCT03286023</nct_id>
  </id_info>
  <brief_title>Stereotactic Radiotherapy for Brain Metastases</brief_title>
  <acronym>CKBrainMeta</acronym>
  <official_title>Stereotactic Radiotherapy for Patients With Brain Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Francois Baclesse, Luxembourg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Francois Baclesse, Luxembourg</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Stereotactic radiotherapy is an innovative treatment enabling to target accurately brain
      metastases. The aim of this study is to evaluate tumoral response and acute and late toxicity
      of this treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of tumoral response</measure>
    <time_frame>4 weeks after treatment</time_frame>
    <description>Evaluation of response using Magnetic resonance imaging (Recist criteria)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of tumoral response</measure>
    <time_frame>8 weeks after treatment</time_frame>
    <description>Evaluation of response using Magnetic resonance imaging (Recist criteria)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of toxicity</measure>
    <time_frame>1, 3, 6, 9, 12, 15 months after treatment</time_frame>
    <description>Evaluation of toxicity using CTCAE v4.0</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Metastasis Brain</condition>
  <arm_group>
    <arm_group_label>Stereotactic radiation</arm_group_label>
    <description>Stereotactic radiation for brain metastases</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>stereotactic radiotherapy</intervention_name>
    <description>stereotactic radiotherapy for brain metastases</description>
    <arm_group_label>Stereotactic radiation</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with brain metastases
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Situation 1: in case of several cerebral metastases. In this case, the maximum of
             cerebral metastases is 3, and the maximum diameter of the largest can not exceed 3 cm.
             The other two ones can not exceed 1 cm or even maximum 2 cm in diameter for one of the
             two. The same principle will remain valid in the presence of 2 metastases.

          -  Situation 2: in the case of a single metastasis, the diameter should be a maximum of 3
             cm

          -  Situation 3: in case of metastasis supposed to be radioresistant (renal
             adenocarcinoma, sarcoma, melanoma ...), only a single metastasis of not more than 3 cm
             in diameter will be accepted. A primary resection followed by radiotherapy will be
             preferred.

          -  Situation 4: In case of localization near a structure at risk (contact with anterior
             optical pathways, central nuclei or the brainstem or localization in these
             structures), a maximum number of 3 metastases may be accepted. However, that included
             in or close to the risk structure can not exceed 2 cm in diameter and the other two,
             located outside a risk structure will have a diameter not exceeding 1 or even maximum
             2 cm.

          -  Situation 5: single metastasis of maximum 3 cm in a context of re-irradiation, the
             whole encephalon having already received the dose of 10 X 3 Gy or its biological
             equivalent of dose.

          -  Signed informed consent

        Exclusion Criteria:

          -  Impossibility of performing an MRI or a CT-scan of the brain with injection of
             contrast agent

          -  Metastases greater than 3 cm at the start
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Philippe Nickers, MD, PhD</last_name>
    <phone>00352571167200</phone>
    <email>philippe.nickers@baclesse.lu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Charlotte Lieunard</last_name>
    <phone>00352571167200</phone>
    <email>charlotte.lieunard@baclesse.lu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Francois Baclesse</name>
      <address>
        <city>Esch-sur-Alzette</city>
        <state>SUD</state>
        <zip>L-4240</zip>
        <country>Luxembourg</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe Nickers, MD, PhD</last_name>
      <phone>00352571167200</phone>
      <email>philippe.nickers@baclesse.lu</email>
    </contact>
    <contact_backup>
      <last_name>Charlotte Lieunard</last_name>
      <phone>00352571167200</phone>
      <email>charlotte.lieunard@baclesse.lu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Luxembourg</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 7, 2017</study_first_submitted>
  <study_first_submitted_qc>September 15, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 18, 2017</study_first_posted>
  <last_update_submitted>September 15, 2017</last_update_submitted>
  <last_update_submitted_qc>September 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>brain metastases</keyword>
  <keyword>stereotactic radiation</keyword>
  <keyword>cyberknife</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

